Biogen Inc logo

BIIBV - Biogen Inc Share Price

$259.61 5.7  2.2%

Last Trade - 01/02/17

Large Cap
Market Cap £31.51bn
Enterprise Value £34.31bn
Revenue £10.42bn
Position in Universe th / 6543
Unlock BIIBV Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
9,703 10,764 11,449 12,274 13,453 14,378 13,393 11,263 +8.2%
+59.1 +27.0 +19.1 -3.4 +31.4 +38.0 +2.29 -25.4
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BiogenInc revenues decreased 1% to $10.59B. Net income decreased18% to $3.64B. Revenues reflect Rest of World segmentdecrease of 7% to $3B, United States segment decrease of 3%to $4.8B. Net income also reflects Other Research anddevelopment increase of 45% to $2.2B (expense), FVAdjustments of Financial Investments decrease from $150.5M(income) to $246.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BIIBV Revenue Unlock BIIBV Revenue

Net Income

BIIBV Net Income Unlock BIIBV Revenue

Normalised EPS

BIIBV Normalised EPS Unlock BIIBV Revenue

PE Ratio Range

BIIBV PE Ratio Range Unlock BIIBV Revenue

Dividend Yield Range

BIIBV Dividend Yield Range Unlock BIIBV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIIBV EPS Forecasts Unlock BIIBV Revenue
Profile Summary

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated April 1, 1997
Public Since September 17, 1991
No. of Shareholders: 540
No. of Employees: 7,400
Sector Healthcare
Industry Pharmaceuticals
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 153,881,597
Free Float (0.0%)
Eligible for
BIIBV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BIIBV
Upcoming Events for BIIBV
Frequently Asked Questions for Biogen Inc
What is the Biogen Inc share price?

As of 01/02/17, shares in Biogen Inc are trading at $259.61, giving the company a market capitalisation of £31.51bn. This share price information is delayed by 15 minutes.

How has the Biogen Inc share price performed this year?

Shares in Biogen Inc are currently trading at $259.61 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biogen Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Biogen Inc?

There are no analysts currently covering Biogen Inc.

When will Biogen Inc next release its financial results?

Biogen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Biogen Inc dividend yield?

Biogen Inc does not currently pay a dividend.

Does Biogen Inc pay a dividend?

Biogen Inc does not currently pay a dividend.

When does Biogen Inc next pay dividends?

Biogen Inc does not currently pay a dividend.

How do I buy Biogen Inc shares?

To buy shares in Biogen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biogen Inc?

Shares in Biogen Inc are currently trading at $259.61, giving the company a market capitalisation of £31.51bn.

Where are Biogen Inc shares listed? Where are Biogen Inc shares listed?

Here are the trading details for Biogen Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BIIBV
What kind of share is Biogen Inc?

We were not able to load our ranking data for Biogen Inc

Is there a Biogen Inc share price forecast 2021?

We were not able to load any forecast data for Biogen Inc.

How can I tell whether the Biogen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogen Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $259.61, shares in Biogen Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biogen Inc PE Ratio?

We were not able to find PE ratio data for Biogen Inc.

Who are the key directors of Biogen Inc?

Biogen Inc's management team is headed by:

Susan Alexander - EVP
Nancy Leaming - IND
Stelios Papadopoulos - CHM
Alexander Denner - IND
Caroline Dorsa - IND
Alfred Sandrock - EVP
Michel Vounatsos - CEO
Ginger Gregory - CHO
Chirfi Guindo - EVP
Daniel Karp - EVP
Robin Kramer - CAO
Jesus Mantas - IND
William Hawkins - IND
Alphonse Galdes - EVP
Michael McDonnell - CFO
Who are the major shareholders of Biogen Inc?

Here are the top five shareholders of Biogen Inc based on the size of their shareholding:

Similar to BIIBV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.